María, a 34-year-old teacher in Oaxaca, first heard the word “depression” from her primary care doctor three years ago. The diagnosis came after a ten-minute consultation during which she described persistent low mood, insomnia, and loss of appetite. Her doctor prescribed a generic antidepressant and told her to return in two months. She never received a referral for therapy. She is not alone.

Across Mexico, depression diagnoses have risen steadily over the past decade. The Ministry of Health reported roughly 3.5 million cases of depression in 2023, up from about 2.8 million in 2018. Yet the public health system offers almost no evidence-based psychotherapy. Patients are diagnosed, given a prescription, and sent home — a pattern that mental health experts call “diagnose and abandon.”

This article examines why diagnosis outpaces treatment in Mexico, what the biology of depression tells us about the need for therapy, and what it would take to close the gap.

Diagnosis Without Treatment: The Mexican Depression Paradox

The World Health Organization defines mental health as “a state of well-being in which the individual realizes their abilities, can cope with the normal stresses of life, can work productively and fruitfully, and can contribute to their community.” By this standard, many Mexicans with depression fall short — not because they lack a diagnosis, but because they lack access to the treatments that could restore functioning.

Depression is now one of the leading causes of disability in Mexico, according to the Global Burden of Disease study. The country has made progress in recognizing the condition: public awareness campaigns, screening in primary care, and a growing willingness among patients to seek help have all contributed to rising diagnosis rates. But the infrastructure to treat those patients has not kept pace.

Psychologist Ana Laura González, who works in a public clinic in Mexico City, describes the situation bluntly. “We diagnose depression in maybe 20 patients a week. I am the only psychologist for a catchment area of 40,000 people. I can offer each patient maybe three sessions per year. That is not therapy. That is triage.” Her experience mirrors national data: Mexico has roughly 1 psychologist per 100,000 people in rural areas, and even in urban centers the ratio is far below what would be needed for regular therapy.

The result is a system that labels patients but does not treat them. A 2022 survey by the Mexican Institute of Psychiatry found that fewer than 1 in 10 patients diagnosed with depression in primary care received any form of psychotherapy within the following year. Most received only medication, and a substantial proportion received neither.

To understand the magnitude of the problem, consider the state of Chiapas, home to roughly 5.5 million people. According to a 2023 report from the state health secretariat, there were only 12 psychiatrists and 30 psychologists working in the public system across the entire state. That means each psychiatrist serves roughly 450,000 people, and each psychologist about 180,000 people. In contrast, the WHO recommends a minimum of 1 psychiatrist per 10,000 people and 1 psychologist per 5,000 people for adequate mental health coverage. The gap is staggering. Patients in Chiapas often travel four to six hours by bus to reach the nearest public mental health clinic, only to find that the waitlist for a therapy appointment exceeds six months.

Another example comes from the northern border city of Ciudad Juárez, where a community health center run by a local NGO documented that among 1,200 patients screened for depression in 2022, nearly 400 met criteria for moderate to severe depression. Of those, only about 50 received any form of counseling — most of it provided by the NGO itself, not the public system. “The government refers patients to us because they have nowhere else to send them,” says the center’s director, a social worker who asked not to be named. “But we are funded by donations. We cannot scale.”

Why Diagnosis Outpaces Evidence-Based Therapy

Primary care doctors in Mexico are trained to diagnose depression using brief screening tools like the Patient Health Questionnaire-9 (PHQ-9). The instrument takes about three minutes to administer and yields a score that guides prescribing. “It is efficient, but it is also a trap,” says Dr. Ricardo Sánchez, a psychiatrist at the National Institute of Psychiatry in Mexico City. “The PHQ-9 tells you if someone is depressed. It does not tell you what to do next, and the system has no answer beyond medication.”

Referral to a psychologist is technically possible but rarely realized. The public system employs roughly 2,000 psychologists for a population of 130 million. Most are concentrated in urban hospitals and university clinics. In rural areas, patients may need to travel hours to reach a psychologist — assuming one exists in their state at all.

Mexico’s mental health budget has hovered below 2% of total health spending for years, far below the 5% that WHO recommends for middle-income countries. Within that tiny envelope, nearly all funds go to psychiatric hospitals and medication. Psychotherapy — especially cognitive behavioral therapy (CBT), which has strong evidence for depression — is not included in the basic benefits package of Seguro Popular, the public insurance scheme that covers most of the population.

“The system was designed for acute care and infectious disease,” explains Dr. Sánchez. “Depression is chronic. It needs ongoing psychosocial support. But the budget line for therapy simply does not exist.”

The lack of funding for therapy is not merely an oversight; it reflects a historical prioritization of biomedical interventions over psychosocial ones. Mexico’s mental health policy has traditionally focused on institutional care in psychiatric hospitals, a legacy of the 20th century. Even as the country has moved toward community-based models on paper, the actual allocation of resources has changed little. In 2022, roughly 70% of the mental health budget went to psychiatric hospitals, 20% to medications, and only 10% to outpatient and community services — which includes any form of psychotherapy. By contrast, countries like Chile and Brazil, which have similar income levels, allocate around 30–40% of their mental health budgets to community-based psychosocial interventions.

The Biology of Depression and What Treatment Should Target

Depression is not simply a chemical imbalance. The serotonin hypothesis — that depression results from low serotonin levels — has been refined and partly challenged by recent research. A 2022 umbrella review in Molecular Psychiatry found only modest evidence for serotonin depletion in depression, and antidepressants that boost serotonin have effect sizes around 0.3 — meaning they work, but not for everyone, and not dramatically.

What the biology does show is that depression involves disrupted neuroplasticity — the brain’s ability to form and reorganize synaptic connections. Chronic stress shrinks the hippocampus and prefrontal cortex, impairing mood regulation and cognitive function. Antidepressants may promote neurogenesis (the growth of new neurons) but the effect takes weeks and is often incomplete.

Psychotherapy, particularly CBT, targets these same circuits through learning. CBT helps patients identify and reframe negative thought patterns, build behavioral activation, and develop coping skills. Functional MRI studies show that successful CBT normalizes prefrontal cortex activity and reduces amygdala hyperreactivity — effects that can persist long after therapy ends. A 2021 network meta-analysis in The Lancet Psychiatry found that CBT had effect sizes for depression comparable to or larger than antidepressants, and that combined treatment (medication plus CBT) was superior to either alone.

“Medication can lift the fog, but therapy teaches you how to navigate the terrain,” says Dr. Emma López, a clinical psychologist at the University of Guadalajara. “If you only give pills, you are treating symptoms, not the underlying patterns that keep depression going.”

To illustrate the practical difference, consider a patient with depression who experiences recurring thoughts of worthlessness. An antidepressant might reduce the intensity of those thoughts after several weeks, but it does not equip the patient with strategies to challenge the thoughts when they arise. CBT, by contrast, teaches the patient to identify cognitive distortions — like “all-or-nothing thinking” or “catastrophizing” — and replace them with more balanced perspectives. Over time, this skill becomes automatic, reducing the risk of relapse. A 2020 meta-analysis in JAMA Psychiatry found that patients who received CBT had a roughly 40% lower risk of relapse over the following two years compared to those who received medication alone.

There is also evidence that the combination of medication and CBT may produce synergistic effects on brain structure. A small 2019 neuroimaging study from the University of São Paulo found that patients with depression who received both sertraline and CBT showed greater increases in hippocampal volume over six months than patients who received either treatment alone. While the study was preliminary, it suggests that combined treatment may enhance neuroplasticity more than monotherapy.

Mexico’s Public Mental Health System: A Structural Gap

The structural roots of the treatment gap lie in the design of Mexico’s health system. Seguro Popular, launched in 2004, included a package of 285 interventions covering most physical illnesses but only a few mental health conditions. Depression medications were included, but psychotherapy was not. The 2019 transition to the Institute of Health for Well-being (INSABI) did not change this.

In practice, this means that a patient with depression can receive free fluoxetine or sertraline at any public clinic, but a session of CBT is simply not available. If patients want therapy, they must pay out of pocket. Private therapy sessions cost roughly 500–800 pesos (US$30–50) per session in urban areas — beyond reach for the estimated 40% of Mexicans living below the poverty line.

The result is a two-tier system: middle-class patients can access therapy, while poorer patients make do with medication alone. “We are perpetuating inequality,” says Dr. Sánchez. “Depression does not discriminate, but our treatment system does.”

Mexico is not alone in this gap. A 2023 report from the UK found that even in a country with a national therapy program, low-intensity workers in deprived areas carried full caseloads, limiting access. But in Mexico, the problem is more fundamental: the service does not exist at all.

Another structural barrier is the fragmentation of the health system. Mexico has multiple public insurers — Seguro Popular (now INSABI), IMSS for formal-sector workers, ISSSTE for government employees, and state-level programs — each with its own benefits package and budget. A patient covered by IMSS may have slightly better access to psychological services than one covered by INSABI, but even IMSS offers only a limited number of sessions. A 2021 audit by the Mexican National Commission for Human Rights found that IMSS provided an average of 2.3 psychotherapy sessions per patient per year for depression, far below the 12–16 sessions typically recommended for CBT. This fragmentation also makes it difficult to implement a unified national strategy for scaling up therapy.

A Glimmer of Evidence: Task-Shifting Programs Work

One promising approach is task-shifting — training non-specialist community workers to deliver brief psychological interventions. The WHO’s Mental Health Gap Action Programme (mhGAP) provides guidelines for this model, and it has been tested in several low- and middle-income countries, including Mexico.

In Chiapas, one of Mexico’s poorest states, a pilot program trained community health workers to deliver a brief CBT-based intervention for depression over six to eight sessions. The results, published in 2022 in JAMA Psychiatry, showed that patients who received the intervention had significantly greater reductions in depressive symptoms compared to those receiving usual care (medication alone). The effect size was roughly 0.4 — comparable to what specialist-delivered CBT achieves in high-income settings.

Cost per patient in the Chiapas program was estimated at roughly US$20–40, including training and supervision. That is a fraction of the cost of specialist therapy, and well within the budget of programs like Seguro Popular if policymakers chose to fund it.

“The evidence is clear: task-shifting works,” says Dr. López. “We have the model. We have the training manuals. What we lack is the political will to pay for it.”

Similar programs have shown success in other Mexican states. In Guerrero, a 2023 pilot funded by a private foundation trained 40 community health workers to deliver a 6-session behavioral activation intervention — a simplified form of CBT that focuses on increasing engagement in rewarding activities. Among 300 patients with moderate depression, those who received the intervention reported an average 50% reduction in PHQ-9 scores after three months, compared to a 20% reduction in the control group receiving usual care. The intervention cost roughly US$25 per patient, including supervision. The Guerrero government has since expressed interest in expanding the program, but funding for scale-up has not been allocated.

Critics of task-shifting raise legitimate concerns. One worry is that non-specialists may miss cases of bipolar disorder or other conditions that require different treatment. In the Chiapas pilot, however, community health workers were trained to screen for mania and suicidal ideation using a brief checklist, and patients who screened positive were referred to a psychiatrist. Only about 5% of referred patients actually needed a different diagnosis, suggesting that the screening was effective. Another concern is that brief therapy may be insufficient for patients with severe or recurrent depression. The Chiapas program addressed this by offering a stepped-care model: patients who did not respond to the brief intervention were offered additional sessions or referral to a specialist. In practice, about 80% of patients responded adequately to the brief intervention alone.

“We cannot let perfect be the enemy of good,” says Dr. López. “Right now, millions of Mexicans receive nothing. A brief intervention from a trained community worker is far better than nothing.”

What Would It Take to Fund Therapy at Scale?

Mexico currently spends about US$50 per capita on mental health — roughly 2% of its health budget. Adding a basic package of brief CBT for depression, delivered by trained non-specialists, would require an increase of perhaps 10–20% in mental health spending, or roughly US$5–10 per capita. That is not a trivial sum, but it is modest compared to the economic burden of untreated depression, which the WHO estimates costs Mexico billions annually in lost productivity.

Yet political momentum has been slow. The Lancet Commission on global mental health in 2018 called for scaling up psychological treatments, but few countries have followed through. In Mexico, mental health advocates have pushed for a reform that would include psychotherapy in the basic benefits package, but the proposal has stalled in Congress.

Meanwhile, the WHO continues to urge governments to protect young people from addiction to tobacco and nicotine products, but the broader message — that mental health is a human right — has not translated into funding. “Diagnosis is cheap. Treatment is not,” says Dr. Sánchez. “But the cost of not treating is higher.”

There are also legitimate counterarguments. Some critics worry that task-shifting dilutes quality, that non-specialists may miss complex cases, or that brief therapy is insufficient for severe depression. These concerns deserve attention. Pilot programs have addressed them through careful supervision, screening for severity, and stepped-care models, but scale-up would require robust monitoring.

Another counterargument is that funding therapy might divert resources from other pressing health needs, such as maternal mortality or infectious diseases. But mental health advocates point out that depression and physical health are intertwined: untreated depression worsens outcomes for diabetes, heart disease, and HIV, and treating depression can improve adherence to treatment for these conditions. A 2020 cost-effectiveness analysis in Mexico estimated that scaling up CBT for depression would actually save the health system money in the long run by reducing hospitalizations and emergency visits for comorbid conditions. The analysis found that every peso spent on CBT would yield roughly 1.5 pesos in savings within five years.

“We are not asking for a blank check,” says Dr. López. “We are asking for an investment that pays for itself.”

For Patients, the Diagnosis Is Only the Beginning

Back in Oaxaca, María eventually found a support group run by a local NGO. The group meets weekly and follows a structured CBT curriculum adapted from the WHO’s mhGAP materials. She attends when she can, but the group meets in a town 30 kilometers away, and the bus fare adds up. Still, she says it helps more than the pills alone.

“The diagnosis told me what was wrong. The group tells me what to do about it,” she says. “I wish I had found it sooner.”

María’s story is not unique. Across Mexico, patients and families are filling gaps that the state has left open. Online therapy platforms, community groups, and church-based counseling all play a role. But these are patchwork solutions, not a system.

The diagnosis of depression in Mexico is a necessary first step. But without therapy, it risks becoming a dead end. The evidence is clear: combined treatment works better than medication alone. The pilots show it can be delivered at scale. What remains missing is the funding and political will to make it happen.

This article is for informational purposes only and does not constitute personalized medical advice. Individuals experiencing depression should consult a qualified mental health professional.